



ProPharmaceuticalsGroup

Pro Pharmaceuticals Group Pty LTD

ABN: 20 605 457 430

www.propg.com.au

Dear Healthcare Professional,

Shortage of OZEMPIC 0.25/0.5 mg semaglutide (rys) 1.34 mg/mL solution for injection pre-filled pen

The Australian registered medicine, OZEMPIC 0.25/0.5 mg semaglutide (rys) 1.34 mg/mL solution for injection pre-filled pen AUST R: 308324 (Sponsor: Novo Nordisk Pharmaceuticals Pty Ltd) is currently in shortage.

Pro Pharmaceuticals Group has arranged for the supply of an alternative product, **OZEMPIC semaglutide 0.25mg solution for injection pre-filled pen (UK)**. This product is NOT registered in Australia and supply is authorised under an exemption granted by the Therapeutic Goods Administration (TGA) under section 19A of the Therapeutic Goods Act 1989 until **28th February 2023** for the following indication(s):

OZEMPIC is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise:

- *as monotherapy when metformin is not tolerated or contraindicated.*
- *in addition to other medicinal products for the treatment of type 2 diabetes.*

OZEMPIC semaglutide 0.25mg solution for injection pre-filled pen (UK) is registered and marketed in the UK by Novo Nordisk A/S.

Pro Pharmaceuticals Group recommends that healthcare professionals refer to the Australian approved Product Information for recommended dosing for various indications.

Please note, OZEMPIC semaglutide 0.25mg solution for injection pre-filled pen (UK) delivers only 0.25 mg of semaglutide per dose, whereas OZEMPIC 0.25/0.5 mg semaglutide (rys) 1.34 mg/mL solution for injection pre-filled pen (AUST R: 308324) delivers doses of either 0.25 mg OR 0.5 mg of semaglutide.

As such, Health professionals should provide additional counselling to patients using OZEMPIC semaglutide 0.25mg solution for injection pre-filled pen (UK), who required to administer a 0.5 mg dose of semaglutide. Specifically, Health professionals should inform patients that:

- **two 0.25 mg doses of semaglutide are required to be administered once weekly**
- **each 0.25 mg dosage is to be injected at a different site;**
- **a new needle is required to be used for each dosage administered; and**
- **additional NovoFine Plus needles will be required, as the amount of needles provided with OZEMPIC semaglutide 0.25mg solution for injection pre-filled pen (UK) will not be sufficient to administer all doses.**

Reporting suspected adverse events is important for the continued monitoring of the safety of all medicines. Any adverse events which are experienced with **OZEMPIC semaglutide 0.25mg solution for injection pre-filled pen (UK)** must be reported by healthcare professionals, pharmacists and patients to the TGA at <https://www.tga.gov.au/reporting-problems> or to Pro Pharmaceuticals Group on 1300077674 or email regulatory@propg.com.au

Any product complaints with **OZEMPIC semaglutide 0.25mg solution for injection pre-filled pen (UK)** should be reported to Pro Pharmaceuticals Group on 1300 077674 or email regulatory@propg.com.au

For any orders please contact Pro Pharmaceuticals Group on 1300077674 or email orders@propg.com.au

Please forward this information to relevant staff members in your organisation.

For further information, please contact Pro Pharmaceuticals Group on 1300077674 or email info@propg.com.au

Sincerely,

Sandip Manku – Director Pro Pharmaceuticals Group